Uncategorized
Cross-functional Perspectives Are Crucial For Risk Assessment
Risk assessment must go beyond the concerns of operations or monitoring teams and span the entire organization – because the conversation is no longer just about monitoring. Read More
KRI Trending Graphs and Ending the Groundhog Day Loop
The famous quote “Those who fail to learn from history are doomed to repeat it” seems appropriate when describing the pharmaceutical industry, at least according to our track record over the last few decades. It often feels like Groundhog Day, and we are Bill Murray hitting the alarm clock before realizing “Oh, here we go again!” Read More
Get The Return You Need On Your mHealth Investment
You just decided to invest a significant portion of your innovation budget to power your clinical trial with new mobile health technology. Now what? Read More
Risk-based Monitoring: People, Process & Systems In Motion
Much like driving a car on new roads, you don’t necessarily know what is around the next bend, so you must constantly monitor your surroundings. Read More
Medical Coding Plays Vital Role In Clinical Trial Speed
Imagine that you are the director of clinical systems at a life science company. Your goal is to ensure that the clinical trial succeeds. Read More
Data Mining as a Path to Better Trial Design
The prospects of Big Data are tantalizing for the life sciences industry, but there’s still much left to do with small data. Read More
Back to the 1980s…Of Clinical Research
Part one of a two-part series about the perceived challenges of introducing tech in clinical research as well as the groundbreaking opportunities for tech in the field. Read More
Does Accuracy Really Matter for mHealth Wearable Devices?
Lately there’s been questions about the accuracy of mHealth wearable devices. Read More
Forget Big Data — Let's Talk Smart Data
There were two interesting posts this past week from Bernard Marr at Forbes and Pam Baker at FierceBigData on how big data will evolve and the predicted impacts on businesses. Read More
Time for Pharma to Catch Up With the FDA
Pharma's sentiment that the federal government’s policies perpetually lag behind innovations pioneered by the private sector has resulted in a vicious cycle of stagnated progress. Read More
